BioCentury
ARTICLE | Finance

Community chorus

How Viehbacher expects Boston Pharma to spend its $600 million

November 23, 2015 8:00 AM UTC

Newly formed Boston Pharmaceuticals is armed with $600 million to occupy one section of the drug development continuum: IND through Phase II proof of concept. To do so, the company plans to amass 20-25 assets and employ the Chorus virtual drug development model of Eli Lilly and Co. (NYSE:LLY).

Boston Pharmaceuticals CEO Robert Armstrong is familiar with the model, as he was VP of global external R&D at Lilly. ...